Accelerating Access. Empowering Innovation. Advancing Equity.
The Global Collaborative Centre for Medical Countermeasures (GCMC) is TechInvention’s EU-GMP-compliant facility designed to facilitate the end-to-end translation of vaccine innovations into commercially scalable, regulatory-compliant products, enabling seamless progression from R&D to market deployment.
Recognized by the WHO World Local Production Forum and featured at the VaxHub Global launch, GCMC aims to bridge the critical gap of vaccine access and equity, particularly for low- and middle-income countries (LMICs), by connecting lab-scale innovation with real-world impact.
Why GCMC?
In the biotech healthcare sector, Centres of Research Excellence comprising startups, academic institutes, R&D organisations, and SMEs drive scientific innovation with cutting-edge technologies. However, they often face challenges in GMP scale-ups with regulatory approvals and tech transfers.
TechInvention’s GCMC acts as an integrated global technology development and transfer hub, serving as a one-stop solution for capacity building in LMICs. It enables the rapid development and GMP scale-up of essential vaccines for biosecurity in collaboration with these centres of Research excellence, aligned with One Health objectives. The output includes tech packs that are process optimised, scaled-up, IP secured, regulatory approved backed by clinical data, ready for commercial-scale manufacturing.
- Our focus at GCMC is to help build solutions that are
- Compliant
- Cost-effective
- Competitive
- Celerity
Our Facility
Strain-to-Supply Infrastructure designed to accelerate end-to-end vaccine development:
Two Parallel Upstream Processing (USP) Suites
Equipped with single-use bioreactors (100L, 500L) and stainless-steel systems (50L, 200L) for production of proteins, peptides, and polysaccharides.
Independent Downstream Processing (DSP) Suites
Integrated with each USP suite, featuring high-efficiency purification technologies.
Flexible Drug Product (DP) Manufacturing
3-in-1 combi line for vials (liquid/lyophilized), pre-filled syringes, and cartridges.
Next-Gen mRNA/saRNA Suite
Fully automated and scalable for both prophylactic and therapeutic applications.
AI/ML, Computational Biology & NGS Labs
Accelerate R&D through smart, data-driven workflows.
Integrated Quality, Regulatory, IP & Training Hub
Supports global compliance, submissions, and skill development.
Green by Design
Solar panels, zero liquid discharge, rainwater harvesting, and IoT-enabled energy optimization.
Write to us at connect@techinvention.biz.
Our Facility
Strain-to-Supply Infrastructure designed to accelerate end-to-end vaccine development:
Parallel Upstream Processing (USP) Suites
Single-use bioreactors (100L, 500L) and stainless-steel systems (50L, 200L) for proteins, peptides, and polysaccharides.
Independent Downstream Processing (DSP) Suites
Integrated with each USP suite, featuring high-efficiency purification technologies.
Flexible Drug Product (DP) Manufacturing
3-in-1 combi line for vials (liquid/lyophilized), pre-filled syringes, and cartridges.
Next-Gen mRNA/saRNA Suite
Fully automated and scalable for both prophylactic and therapeutic applications.
AI/ML, Computational Biology & NGS Labs
Accelerate R&D through smart, data-driven workflows.
Integrated Quality, Regulatory, IP & Training Hub
Supports global compliance, submissions, and skill development.
Green by Design
Solar panels, zero liquid discharge, rainwater harvesting, and IoT-enabled energy optimization.